본문으로 건너뛰기
← 뒤로

Metabolic dysfunction-associated steatotic liver disease and acute leukemias .

1/5 보강
Leukemia & lymphoma 📖 저널 OA 9.2% 2022: 1/1 OA 2025: 2/55 OA 2026: 15/137 OA 2022~2026 2026 p. 1-10
Retraction 확인
출처

Salah T, Stahl M, Bewersdorf JP

📝 환자 설명용 한 줄

Metabolic dysfunction-associated steatotic liver (MASLD) is a prevalent cause of chronic liver disease, affecting roughly 38% of adults in the USA.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Salah T, Stahl M, Bewersdorf JP (2026). Metabolic dysfunction-associated steatotic liver disease and acute leukemias .. Leukemia & lymphoma, 1-10. https://doi.org/10.1080/10428194.2026.2640454
MLA Salah T, et al.. "Metabolic dysfunction-associated steatotic liver disease and acute leukemias .." Leukemia & lymphoma, 2026, pp. 1-10.
PMID 41879616 ↗

Abstract

Metabolic dysfunction-associated steatotic liver (MASLD) is a prevalent cause of chronic liver disease, affecting roughly 38% of adults in the USA. Growing evidence suggests that metabolic conditions such as MASLD and obesity may influence the epidemiology, biology, and clinical outcomes of patients with leukemia. Limited studies indicate that MASLD's pro-inflammatory milieu may contribute to clonal hematopoiesis and leukemogenesis by promoting DNA damage, clonal expansion of mutated hematopoietic stem cells, and providing pro-survival signals. Here we review the current evidence linking MASLD with acute leukemias. We discuss epidemiological trends, mechanistic insights from preclinical and clinical studies, and prognostic implications of MASLD in acute myeloid leukemia and acute lymphoblastic leukemia. We highlight that while metabolic dysfunction appears to adversely impact leukemia outcomes, the interactions are complex and occasionally paradoxical. Finally, we identify key gaps in the literature, underscoring the need for dedicated studies on MASLD in leukemia patients and whether modifying MASLD can improve leukemia outcomes.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반